Cocrystal Pharma, Inc. (COCP) - Form 8-K Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc., a Delaware corporation, filed this Current Report on Form 8-K on November 14, 2025. The filing serves to announce the Company's results of operations for the fiscal quarter ended September 30, 2025, and to provide certain business updates. The Company's common stock trades on The Nasdaq Capital Market under the symbol "COCP."
Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were issued via a press release (Exhibit 99.1) but does not embed the financial data within the 8-K text itself.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It references a press release for the full details of the quarterly results and business updates.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and the attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not incorporated by reference into any other Company filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in the text of this 8-K.
Key Facts for Investor Verification
- Review Exhibit 99.1 (Press Release dated November 14, 2025) for actual financial figures and operational details.
- Verify the specific business updates mentioned in the press release, as they are not summarized in the 8-K text.
- Note that the financial data in this filing is not incorporated by reference into future SEC filings.
- Confirm the Company's status as an emerging growth company (indicated as unchecked in the form).